Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.

Bookstaver DA, Sparks K, Pybus BS, Davis DK, Marcsisin SR, Sousa JC.

Ann Pharmacother. 2018 Mar;52(3):251-256. doi: 10.1177/1060028017738262. Epub 2017 Oct 19.

PMID:
29047306
2.

Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.

Jin X, Potter B, Luong TL, Nelson J, Vuong C, Potter C, Xie L, Zhang J, Zhang P, Sousa J, Li Q, Pybus BS, Kreishman-Deitrick M, Hickman M, Smith PL, Paris R, Reichard G, Marcsisin SR.

Malar J. 2016 May 17;15(1):280. doi: 10.1186/s12936-016-1329-z.

3.

Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.

Marcsisin SR, Reichard G, Pybus BS.

Pharmacol Ther. 2016 May;161:1-10. doi: 10.1016/j.pharmthera.2016.03.011. Epub 2016 Mar 22. Review.

4.

Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.

Vuong C, Xie LH, Potter BM, Zhang J, Zhang P, Duan D, Nolan CK, Sciotti RJ, Zottig VE, Nanayakkara NP, Tekwani BL, Walker LA, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Smith B, Marcsisin SR.

Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9. doi: 10.1128/AAC.00343-15. Epub 2015 Apr 13.

5.

Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.

Opsenica IM, Verbić TŽ, Tot M, Sciotti RJ, Pybus BS, Djurković-Djaković O, Slavić K, Šolaja BA.

Bioorg Med Chem. 2015 May 1;23(9):2176-86. doi: 10.1016/j.bmc.2015.02.061. Epub 2015 Mar 7.

PMID:
25801154
6.

Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.

Potter BM, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, Luong TL, Bandara Herath HM, Dhammika Nanayakkara NP, Tekwani BL, Walker LA, Nolan CK, Sciotti RJ, Zottig VE, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Marcsisin SR.

Antimicrob Agents Chemother. 2015 Apr;59(4):2380-7. doi: 10.1128/AAC.00015-15. Epub 2015 Feb 2.

7.

Enantioselective metabolism of primaquine by human CYP2D6.

Fasinu PS, Tekwani BL, Nanayakkara NP, Avula B, Herath HM, Wang YH, Adelli VR, Elsohly MA, Khan SI, Khan IA, Pybus BS, Marcsisin SR, Reichard GA, McChesney JD, Walker LA.

Malar J. 2014 Dec 17;13:507. doi: 10.1186/1475-2875-13-507.

8.

Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations.

Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.

J Pharmacol Toxicol Methods. 2014 Sep-Oct;70(2):188-94. doi: 10.1016/j.vascn.2014.08.002. Epub 2014 Aug 20.

PMID:
25150934
9.

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Zeng Q, Roncal N, McNulty R, Careagabarja J, Sciotti RJ, Bennett JW, Zottig VE, Deye G, Li Q, Read L, Hickman M, Dhammika Nanayakkara NP, Walker LA, Smith B, Melendez V, Pybus BS.

Malar J. 2014 Jan 3;13:2. doi: 10.1186/1475-2875-13-2.

10.

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.

Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF.

N Engl J Med. 2013 Oct 3;369(14):1381-2. doi: 10.1056/NEJMc1301936. No abstract available.

11.

CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever.

Marcsisin SR, Jin X, Bettger T, McCulley N, Sousa JC, Shanks GD, Tekwani BL, Sahu R, Reichard GA, Sciotti RJ, Melendez V, Pybus BS.

Malar J. 2013 Jun 21;12:214. doi: 10.1186/1475-2875-12-214.

12.

An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model.

Jin X, Pybus BS, Marcsisin R, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V.

Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):139-46.

PMID:
23797843
13.

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.

Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V.

Malar J. 2013 Jun 20;12:212. doi: 10.1186/1475-2875-12-212.

14.

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.

Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V.

Malar J. 2012 Aug 2;11:259. doi: 10.1186/1475-2875-11-259.

15.

Structure-function relationship in the antifreeze activity of synthetic alanine-lysine antifreeze polypeptides.

Wierzbicki A, Knight CA, Rutland TJ, Muccio DD, Pybus BS, Sikes CS.

Biomacromolecules. 2000 Summer;1(2):268-74.

PMID:
11710110

Supplemental Content

Loading ...
Support Center